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The translationally controlled tumor protein (TCTP) is highly conserved among animal species. It is widely expressed in many
diﬀerent tissues. It is involved in regulating many fundamental processes, such as cell proliferation and growth, apoptosis,
pluripotency, and the cell cycle. Hence, it is not surprising that it is essential for normal development and, if misregulated, can
lead to cancer. Provided herein is an overview of the diverse functions of TCTP, with a focus on development. Furthermore, we
discuss possible ways by which TCTP misregulation or mutation could result in cancer.
1. Introduction
TCTP was first identified in tumor cells. Since its mRNA has
all sequence and structural characteristics of translationally
controlledmRNAs, it was named “Translationally Controlled
Tumor Protein” [1, 2]. It is also known under many diﬀerent
names, such as histamine releasing factor (HRF), tumor
protein translationally controlled (Tpt1), p23, and fortilin.
The protein is highly conserved across diﬀerent species [3],
is ubiquitously expressed, but the level of the mRNA varies
depending on the cell type [4, 5] and developmental stage
[6]. A wide range of extracellular stimuli can rapidly regulate
its mRNA level. Examples range from cytokines to calcium
levels [7, 8]. Translational regulation of the mRNA adds
another layer of TCTP level diversity [9].
TCTP expression seems to be highly regulated at many
levels by many distinct mechanisms. It is not surprising that
it is associated with an array of diﬀerent biological activities,
such as the cell cycle [3, 10], apoptosis [11–15], cytoskeleton
[10, 16, 17], protein synthesis [18], immune response [19],
development [6, 20–22], and cancer [11, 23, 24]. In recent
years the protein has attracted most attention on account of
its role in tumor reversion and its crucial role in development
[21, 23]. In this paper we outline what is known so far about
TCTP in development with the underlying molecular events
and discuss how its misregulation might result in cancer.
2. TCTP Promotes Cell Proliferation
and Growth
TCTP knockdown studies in Drosophila cause lethality in
late first-instar larvae and result in reduced cell number, cell
size, and organ size [21]. This indicates an eﬀect on cell
proliferation and growth, which is regulated mainly by the
TOR pathway.
The TOR pathway is regulated by nutrient and energy
availability, as well as hypoxia. It integrates signals from
many pathways, such as insulin signaling, growth factors,
and amino acids. It not only regulates cell growth and
proliferation, but also cell motility, cell survival, protein
synthesis, and transcription. The pathway is named after
the Target of Rapamycin (TOR), a serine-threonine kinase,
encoded by the FRAP1 gene. In the presence of growth-
promoting signals, receptors on the cell membrane are
activated that lead to the activation of the serine-threonine
kinase Akt and ultimately TOR. In mammals, the protein
TOR is either bound to the protein Raptor (complex TOR1)
or to the protein Rictor (complex TOR2). The TOR1
complex is sensitive to the bacterial product rapamycin and
is involved in mRNA translation and ribosome biogenesis.
The other rapamycin-insensitive complex TOR2 regulates
cell survival and the cytoskeleton (reviewed in [25]). It
regulates the cytoskeleton by stimulating various proteins,
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for example, actin fibers [26]. It also phosphorylates the
serine-threonine kinase Akt, which initially leads to TOR
activation [27].
TOR1 is activated by an increase in nutrient levels,
growth factors, and stress [28]. These extracellular signals
activate a cascade of proteins within the cell, leading to
the activation of the GTPase Rheb, that ultimately activates
TOR1. TOR1 then targets various downstream factors, such
as the serine-threonine kinase S6K and the protein 4EBP1
(reviewed in [25]). S6K is known to phosphorylate many
proteins. Onemajor target is the S6 ribosomal protein.When
nutrients are sparse, the S6 ribosomal protein is bound to
the eIF3 complex, which is involved in the initiation of
translation by recognizing the 5′ cap structure of mRNAs.
mRNAs that contain a 5′ polypyrimidine tract, referred to as
5′ TOP, are important targets of eIF3 translational activation
[29, 30]. These transcripts generally encode further riboso-
mal proteins and translation elongation factors. When the
availability of nutrients increases, TOR is activated, causing
an increase of S6K. Ultimately, S6 becomes phosphorylated,
which causes the eIF3 complex to be released resulting in the
activation of translation [31]. Various mRNAs become trans-
lated, in particular the mRNAs with a 5′ TOP region that
encode proteins involved in translation. This subsequently
leads to the production proteins required for translation,
overall leading to the amplification of translation.
The other TOR1 target, 4EBP1, is a translation repressor.
4EBP1 binds to the eukaryotic initiation factor 4E (eIF4E),
which recruits 40S ribosomal subunits to the 5′ end of
mRNAs to initiate translation. Interaction of 4EBP1 and
eIF4E results in the inhibition of translation. Upon TOR1
activation, 4EBP1 is phosphorylated, resulting in the dissoci-
ation from eIF4E, allowing eIF4E to initiate translation [32].
The entire TOR1 cascade and the increased protein syn-
thesis required the activation of Rheb. Studies in Drosophila
showed that mutant Rheb resulted in smaller cell sizes and
numbers, as observed in the absence of TCTP. It was then
determined that TCTP associates with Rhed. This is likely
to be conserved between species, as human TCTP was able
to rescue Drosophila TCTP mutants [21]. This observation
directly links TCTP with the TOR pathway, explaining its
eﬀect on cell proliferation and growth. In the absence of
TCTP, Rhed is no longer active, leading to a decrease in TOR1
activity and ultimately a decrease in protein synthesis in
response to external growth-stimulating stimuli. It is known
that TCTP responds to many external stimuli. This suggests
that the interaction of TCTP with the TOR1 complex might
be the reason for the TCTP responsiveness to many external
signals [7, 8]. It would be interesting to investigate the
connection of TCTP with the TOR2 pathway. Since cells
are smaller in TCTP mutants, it is likely that the TOR2
pathway that also regulates the cytoskeleton is involved. To
test if TCTP has an eﬀect on the TOR2 pathway, one could
analyze the eﬀect of TCTP in the presence of rapamycin.
Since rapamycin inhibits the TOR1 activity, it is possible to
investigate if the absence of TCTP still has a function on the
cell size and growth. If this is the case, it would be interesting
to analyze the level of the major TOR2 components in the
absence of TCTP. Further studies, for example, with mutants
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Figure 1: TCTP can activate the TOR pathway and promote cell
proliferation and growth.
in a TCTP depleted background could help to elucidate if and
where in the TOR2 pathway TCTP could act (Figure 1).
As described above, TOR1 activates the S6K kinase,
which activates S6 and leads to translation of mRNAs, in
particular of mRNAs that contain the 5′ TOP tract [29, 30].
TCTP mRNA itself contains the 5′-TOP domain [9]. This
suggests that TOR1might activate TCTP translation, via S6K
and S6. Since TCTP activates TOR1 by binding to Rheb, the
activator of TOR1, it is possible that TCTP not only activates
TOR1, but also provides a positive feedback mechanism.
Mutating the 5′ TOP domain of TCTP might help to
determine if TCTP is actually activated by this route. If this
is the case, overexpression of S6K should increase TCTP
protein levels, which will in turn promote even more TOR1
activity. S6K could act as a major regulator of TOR1, since
it also inactivates the repressor TOR1 by phosphorylation,
suggesting a positive feedback mechanism [33]. TCTP could
also act in this way, providing a positive feedback mechanism
to upregulate TOR. When TCTP is high, it activates TOR1,
which in turn leads to the phospporylation of S6 by S6K and
increased translation. This might again lead to an increased
TCTP protein level that increases TOR1 activation.
Even though abnormal cell proliferation and growth can
be explained by TCTP interaction with the TOR pathway,
this does not fully explain why development is ultimately
arrested. This suggests that TCTP has also a major function
that lies outside of the TOR pathway.
3. TCTP Inhibits Apoptosis
In the early development of mice, TCTP mRNA and protein
levels are significantly increased from embryonic day E3 to
E5, when they reach a maximum level. Selective depletion
of TCTP in the uterus at E3 resulted in reduced numbers
of implanted embryos compared to wild-type embryos
[34]. In knockout mice, heterozygous mutants of TCTP
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had no obvious developmental eﬀects, but homozygous
mutants were lethal between E9.5 and E10.5 [22]. Severe
abnormalities became most prominent at E5.5, which is
when TCTP level is normally at its highest. Not only did the
mice embryos appear smaller, but the epiblast that eventually
develops into the fetus also contained a significantly lower
cell number. The reason for this was determined to be a
misregulation of apoptosis [22].
Apoptosis is a crucial part of the life of a multicellular
organism. It is a highly regulated process, resulting in
programmed cell death. Insuﬃcient apoptosis may result
in accumulation of mutations and uncontrolled cell pro-
liferation, such as in cancer. Apoptosis can be induced
by extracellular or intracellular signals and involves the
activation of various regulatory proteins that activate the
apoptotic pathway. This process is highly regulated, so that
apoptosis is not induced unnecessarily, and can even be
stopped if the need for apoptosis is no longer required.
The intracellular apoptotic pathway is mainly regulated with
the help of mitochondria, which supplies the cell with
energy. A change in the permeability of the mitochondrial
membrane can cause apoptotic proteins to leak into the
cell. Pores called mitochondrial outer membrane perme-
abilization pores (MACs) regulate the permeability of the
mitochondrial membrane to apoptotic proteins. Proteins
belonging to the Bcl-2 protein family can regulate these
MACs [35]. The protein Bax, when activated, dimerizes
within the mitochondrial membrane. This dimerization
promotes MAC pore formation, causing apoptotic proteins
to enter the cell. In contrast, the proteins Bcl-2 and Mcl-1
inhibit MAC formation, preventing the influx of apoptotic
proteins into the cell (reviewed in [36]). Apoptotic proteins
that can be released viaMACs into the cell are generally called
small mitochondria-derived activator of caspases (SMACs).
These can bind to inhibitors of apoptosis proteins (IAPs)
within the cell. IAPs are usually bound to cysteine proteases
that are referred to as caspases [37]. These caspases are
enzymes that can degrade intracellular proteins, which
ultimately cause the degradation of the entire cell. Often,
these caspases need to be proteolytically cleaved in order to
become active. In addition to SMACs,MAC pores also release
the protein cytochrome c. Cytochrome c can then form a
complex called apoptosome, by binding to ATP, the apoptotic
protease activating factor1 (Apaf1) and procaspase-9. This
results in the proteolytic cleavage of pro-caspase 9 into
the enzymatically active form caspase 9, overall activating
cellular degradation [38].
In a normal cell, the mitochondrial membrane is not
permeable to SMACs. As a result, no cytochrome c is in
the cell to activate caspase 9. Another class of inhibitor, the
IAP proteins, are bound to caspases. Upon an apoptosis-
inducing signal, the mitochondrial membrane is perme-
abilized, releasing SMACs and cytochrome c into the cell.
SMACs bind IAPs, which release caspases, and cytochrome c
converts caspase 9 to its active form (reviewed in [36]). This
results in intracellular digestion and cell death. The necessity
for diﬀerent factors to be exported by the mitochondria
shows the high level of regulation. This is not surprising, as a
malfunction of the system would be detrimental to the cell.
TCTP also seems to play an important role in controlling
the potentially suicidal pathway. It was found to inhibit
the proapoptotic protein Bax that promotes MAC pore
formation by dimerizing in the mitochondrial membrane.
TCTP inserts itself into the mitochondrial membrane,
preventing Bax from dimerizing [22]. This prevents MAC
pore formation and inhibits any flux of apoptosis promoting
factors into the cell [15]. Another study showed that TCTP
also binds to Mcl-1. As discussed above, Mcl-1 inhibits MAC
formation. Since binding of TCTP was found to stabilize
Mcl-1, TCTP increases the block on MAC formation and
ultimately prevents apoptosis [13, 14].
It remains to be investigated what happens to TCTPwhen
apoptosis is initiated. It is possible that the TCTP protein is
actively degraded or isolated from the system, or that the
TCTP mRNA level decreases. In both cases, it is likely that
a factor is required for TCTP inactivation. Pull-down studies
and promoter analysis when apoptosis is induced could help
to find important regulators of TCTP.
4. TCTP in Pluripotency and
Nuclear Reprogramming
During development cells become committed and diﬀeren-
tiate from one cell into many distinct cell types. Embryonic
stem (ES) cells are pluripotent cells derived from the inner
cell mass of the blastocysts of an early embryo. In contrast
to committed or diﬀerentiated cells, pluripotent cells can
diﬀerentiate into any fetal or adult cell type and are capable
of self-renewal and unlimited proliferation [39]. These have
tremendous potential in medicine, as ES cells could be
diﬀerentiated into any cell type or even tissue of the body
and be used for potential cell replacement therapies.
ES cells are characterized by a particular pattern of gene
expression. For example, various genes are upregulated in
ES cells and are frequently used as pluripotency markers.
Oct4 seems to be an important regulator of pluripotency
and diﬀerentiation [40]. It represses or activates expression
of diﬀerent genes, which occurs either directly by binding to
promoter regions or indirectly by neutralising transcription
activators [41]. Oct4, also known as Oct3, is a member of the
POU transcription family [42]. These are transcription fac-
tors that bind via an octameric sequence to an AGTCAAAT
consensus sequence [41]. The gene is expressed in early
mammalian embryos, during gametogenesis, in ES cells [43],
and occasionally in tumours [44]. After gastrulation, Oct4
becomes silent in mouse and human mammalian somatic
cells [45]. In mouse oocytes, Oct4 mRNA is present as
a maternal transcript [46] and it is downregulated when
development proceeds [47]. It is essential, but not suﬃcient
to maintain cells in an undiﬀerentiated state [48]. During
embryonic development, Oct4 is expressed in early blas-
tomeres. Then, it becomes restricted to the inner cell mass,
and is down regulated in the trophectoderm and primitive
endoderm [47]. Oct4 is widely conserved. Homologues
even exist in early amphibian development, where they also
act as suppressors of cell fate commitment. Even though
so far ES cells have not been derived from amphibians,
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the Xenopus laevis version of Oct4, Pou91, was able to fully
support mouse ES cell self-renewal [49]. This suggests a
similar function for Pou91 in pluripotency.
Pluripotency also requires other factors, for example,
the leukaemia inhibitory factor (LIF). LIF is a key molecule
required for self-renewal and pluripotency in mouse ES
cells [50, 51], but not for monkey or human ES cells [52].
It is known to bind to the heterodimer LIF receptor—
gp130 and to activate the transcription factor STAT3 by
phosphorylation [53]. Interestingly, overexpression of the
gene Nanog can bypass the requirement for LIF in mouse
ES cells [54]. Nanog is also required for maintaining the
undiﬀerentiated state of early postimplantation embryos and
ES cells [54, 55], making Nanog an important regulator
of pluripotency. There are also other components required,
such as bone morphogenic proteins (BMP) that activate the
inhibitor of diﬀerentiation (Id), which represses diﬀeren-
tiation [56]. Another important regulator is Sox2, which
cooperatively binds the Oct4 protein and activates genes
promoting pluripotency [57], but represses its inhibitors
[58].
Despite obtaining the ES cells from blastocysts, ES or
ES-cell-like cells can be obtained by nuclear reprogram-
ming, a term introduced to describe the restoration of
the embryonic pattern of gene expression [59]. Nuclear
reprogramming was first demonstrated in nuclear transfer
experiments. Xenopus laevis nuclei of diﬀerentiated cells
were transplanted into enucleated frog eggs. This gave rise
to normal fertile adult frogs, illustrating that diﬀerentiated
cells can become reprogrammed and give rise to an entire
new organism [60, 61]. Another way to reprogram nuclei
was achieved when cells were fused to each other [62, 63].
Cell fusions with ES cells rejuvenated somatic cells that
could diﬀerentiate into many diﬀerent cell types. In these
hybrids the silent gene Oct4 was reactivated [64]. Fusion
experiments with an increased expression of the pluripotency
gene Nanog increased nuclear reprogramming eﬃciency by
200-fold [65]. Nowadays, the most common way somatic
cells are reprogrammed to an embryonic-like pattern of gene
expression is by overexpressing diﬀerent factors, such as
Oct4, Sox2, c-Myc, and Klf4 under ES cell culture conditions
[66]. Surprisingly, Nanog was not required, even though it
seemed to promote nuclear reprogramming in cell fusion
experiments [65]. These ES-like cells had normal ES cell
morphology, a gene expression pattern typical for normal ES
cells and could diﬀerentiate into all three germ layers. They
were named iPS cells, induced pluripotent stem cells [66].
Even though the generation of iPS cells is a very convenient
way to generate ES cells, this approach does not reveal the
mechanism underlying nuclear reprogramming. Also, it does
not identify novel factors that are involved in this process.
To better understand the process of nuclear reprogram-
ming, nuclear transfer experiments of somatic cells into
Xenopus oocytes were carried out. It was found that even
human or mouse nuclei could be reprogrammed by frog
oocytes and induce an ES cell or ES cell-like pattern of
gene expression [67]. For example, genes such as Oct4,
Nanog, and Sox2 became transcriptionally active upon
nuclear transfer [67]. Using this system, novel molecules
were isolated that interact with the promoter region of Oct4.
One of these molecules was TCTP. Further functional assays
revealed that it in fact TCTP changed the transcriptional level
of Oct4 and even Nanog in human nuclei, genes essential for
successful nuclear reprogramming [68]. A similar eﬀect of
TCTP was found in bovine oocytes, suggesting a conserved
function of TCTP in activating pluripotency [69]. TCTP
knockout mice have an abnormal number of cells in the
epiblast [22]. The epiblast is formed from the inner cell mass
of the blastocyst, from which ES cells can be obtained. Since
TCTP activates the pluripotency genes Oct4 and Nanog, it is
possible that, in the TCTP knockout mice, the epiblast does
not develop normally due to misregulation of pluripotency
genes such as Oct4 and Nanog.
It would be interesting to determine if TCTP activates
also other pluripotency genes such as Sox2 and Klf4. TCTP
might promote pluripotency in two diﬀerent ways, namely,
by (1) activating pluripotency genes and (2) inhibiting
somatic gene expression. Genomewide studies in the absence
of TCTP could help to determine what other genes TCTP
regulates. Another important question is whether TCTP is
suﬃcient for nuclear reprogramming and if its overexpres-
sion in somatic cells could replace the four reprogramming
factors used tomake iPS cells. Even if it does not replace these
four factors, it could increase the generation of iPS cells, a
currently very ineﬃcient process.
Nuclear actin polymerization has been reported to be
required for Oct4 activation in Xenopus laevis oocytes [70].
Since TCTP has been found to contain an actin-binding site
[17], it is possible that it might interfere with pluripotency
gene regulation by interfering with actin. Testing actin
polymerization in the absence and presence of TCTP, as
well as the eﬀect on Oct4, would help to understand any
possible interactions required to induce pluripotency. These
experiments could also be analyzed Genomewide, which will
greatly help to elucidate the underlying network required
to establish pluripotency. Using TCTP as bait to pull down
interaction partners together with Genomewide Chromatin
Immunoprecipitation analysis of TCTP and its interaction
partners will also contribute towards understanding how
pluripotency is established.
Another protein that has been found to interact with
TCTP in Xenopus oocytes is nucleoplasmin Npm1 [71].
Similar to TCTP knockout mice, mice deficient in Npm1 are
embryonic lethal and have smaller embryo sizes [72]. Npm1
is a very abundant protein. In fertilized Xenopus eggs, it is
involved in the decondensation and hence transcriptional
activation of the paternal genome provided after normal
fertilization by the sperm (reviewed in [73]). It is possible
that TCTP not only activates pluripotency genes, but also
that it has a role in paternal gene activation by interacting
with Npm1. Disturbing the interaction of TCTP and Npm1
could show if TCTP is also involved in this process. But
it is possible that pluripotency and paternal and maternal
genome activation is actually not that diﬀerent. After all,
when the genome becomes transcriptionally active, it is set
as such, so that it can proliferate and diﬀerentiate into an
entire organism. Hence, zygotic genome activation could be
regarded as nuclear reprogramming that occurs naturally
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in nature, without the need of nuclear transplantation, cell
fusion experiments, or overexpression of a few transcription
factors.
5. Cell Cycle Regulation of TCTP
The cell cycle describes the stages a cell has to go through to
divide and duplicate its genome. In eukaryotes, the cell cycle
is divided into four phases: (1) the G1 phase, in which the
cell grows and makes sure it is prepared for DNA replication,
(2) the S or synthesis phase, where the DNA is duplicated,
the (3) G2 phase, in which the cell ensures it is ready for
mitosis, and (4) the M phase, in which cell growth stops
and the cell divides its DNA and other cellular components
giving rise to two cells. There is also an additional phase,
which is not part of the cell cycle, G0, in which the cell has
exited the cell cycle and has stopped dividing [74]. Since the
cell cycle is crucial for the survival of the cell and generation
of a multicellular organism, the process is highly controlled.
There are many proteins that control each phase and that
detect and repair genetic damage, as well as avoiding the
propagation of mutations [74]. Any misregulation might
result in uncontrolled cell proliferation and ultimately
cancer. The key enzymes regulating the progression from one
phase into the next are called cyclins and cyclin-dependent
kinases. There are also many other proteins, such as the
serine-threonine protein kinase polo-like kinase 1 (PLK1)
and the protein checkpoint with forkhead and ring finger
domains (CHFR).
The protein CHFR is an E3 ubiquitin ligase that can
detect microtubule abnormalities. It delays the G2 to mitosis
transition when it is exposed to altered microtubules.
Microtubules are part of the cytoskeleton and act in mitosis
and move the duplicated genomes into the forming daughter
cells. CHFR is usually present in an inactive form, unable to
carry out ubiquitination. When microtubules are damaged,
CHFR becomes activated [75]. CHFR then ubiquitinates
PLK1 that results in PLK1 degradation [76]. The kinase PLK1
is required in the late G2 and early mitotic phases. It regulates
spindle assembly and centrosome maturation, which is a
microtubule-organizing center. PLK1 phosphorylates and
activates Cdc25C, which dephosphates and activates the
cyclins required for mitosis, the cyclinB/cdc2 complex [77,
78]. Any loss of PLK1 can induce a block in cell cycle
progression and lead to apoptosis. PLK1 overexpression is
frequently observed in connection with centrosome abnor-
malities, improper segregation of chromosomes and tumor
cells.
Although the TOR pathway might be indirectly involved
in cell cycle regulation by responding to growth factors and
energy levels and driving cell proliferation, TCTP seems to be
involved more directly in the cell cycle. For example, TCTP
expression is upregulated upon entry into the cell cycle,
but when overexpressed, cell cycle progression is delayed
[10]. TCTP also has a tubulin-binding site that allows it to
bind to microtubules in a cell-cycle-dependent way. As a
result, it is recruited to the mitotic spindle during metaphase,
but is released at the M/G1 transition [10]. Furthermore,
TCTP interacts with CHFR that interacts with microtubules
[79]. Upon depolymerization of the microtubules, CHFR
and TCTP interaction is diminished. It has been suggested
that this might provide a mechanism by which CHFR senses
microtubule abnormalities that results in CHFR activation,
PLK1 degradation, and ultimately cell cycle arrest [79]. It
would be interesting to determine if CHFR can bind with
the same aﬃnity to microtubules in the absence of TCTP,
or if it is no longer sensitive to microtubule abnormalities
in the absence of TCTP, confirming the proposed model. In
addition to binding to CHFR, TCTP can be phosphorylated
by the substrate of CHFR, PLK1 [80]. This presumably
leads to a decrease in the aﬃnity of TCTP for microtubules
or CHFR. When PLK1 phosphorylation sites on TCTP
are blocked, a dramatic increase in multinucleated cells
is observed suggesting that the completion of mitosis is
inhibited [81]. This suggests that TCTP is crucial in cell cycle
regulation and that its phosphorylation by PLK1 is required
for accurate exit from mitosis. In the TCTP mutants that
cannot become phosphorylated, an increase in apoptosis is
also observed [81]. Bearing in mind that TCTP is involved
in apoptosis, it is possible that PLK1 acts via TCTP to
inhibit apoptosis. TCTP phosphorylation by PLK1 causes
cell cycle progression. It is possible that this modified TCTP
might have inhibitory eﬀects on the apoptotic pathway.
In this way, TCTP could make sure that when cell cycle
progresses no apoptosis is induced. In contrast, if it is not
modified by PLK1 during mitosis, it might induce apoptosis
via the diﬀerent routes described above. It would be revealing
to investigate the role of the modified TCTP protein in
apoptosis.
6. TCTP in Cancer
TCTP has been associated with tumorigenesis and cancer
since its discovery in tumor cells [1, 2]. It was not until
tumor reversion screens that TCTP got attention as a key
player in cancer (Figure 2) [11, 23]. Tumor reversion is a
process by which some cancer cells lose their malignant
phenotype. Studying this process might help to understand
how cancer can be inhibited and ultimately lead to a cure.
To understand this process on a molecular level, tumor cells
were grown in the presence of the H1 parvovirus [23]. This
virus preferentially kills tumor cells, which in turn allows for
selection of cells that revert back to a normal, nonmalignant
phenotype [82, 83]. To identify which genes are most likely
to be involved in this process, the level of gene expression was
compared between malignant and reverted state. The TCTP
gene expression level showed the largest diﬀerence between
malignant and reverted state. A high level associates with
tumorigenesis and a low level with normal cell growth (124
times higher TCTP level in tumor cells versus revertants).
This was confirmed in several diﬀerent tumor cell lines,
suggesting that it is a universal gene that is implicated in
tumor reversal [23]. Furthermore, knockdown experiments
of TCTP in various malignant cell lines increased tumor
reversal by approximately 30% [11].
6 Biochemistry Research International
TCTP
Cancer
MutationMisregulation
Changed 
pathways
TOR Apoptosis Oct4/ Cell cycle Cytoskeleton p53 Protein Protein Immunological
gene expression synthesis secretion changes
Figure 2: Pathways in which TCTP misregulation or mutations
could cause cancer.
The p53 protein is one of the most famous tumor sup-
pressors and is often referred to as the “guardian” of cancer.
It is a transcription factor and regulates the transcription of
various genes. It can activate the transcription of DNA repair
genes when the DNA is damaged, through genes involved
in cell cycle and initiate apoptosis by regulating genes such
as Bax and Bcl-2 [84]. In response to stress such as DNA
damage, it either induces repair genes to repair the damage,
cell cycle arrest to prevent the replication of damaged DNA,
or induces apoptosis to eliminate potentially malignant cells.
Various signals are responsible for whether p53 induces
repair, cell cycle arrest, or apoptosis (reviewed in [85]).
To better understand how TCTP levels control cancer, the
interaction between TCTP and p53 has been studied in more
detail. It was found that TCTP overexpression can lead to
p53 degradation. This was accompanied by the observation
that p53 was no longer able to induce apoptosis [24]. This
suggested that TCTP is an important regulator in the p53
pathway and also links p53 with apoptosis.
MDM2 is a transcriptional target of p53. When over-
expressed, MDM2 ubiquitinates and degrades p53, provid-
ing a negative feedback mechanism. TCTP was found to
inhibit MDM2 autoubiquitination and to promote MDM2-
mediated ubiquitination of p53, which ultimately leads
to p53 degradation [86]. In addition, p53 was found to
downregulate TCTP levels [23] and to promote TCTP
exosome secretion [87, 88]. This shows that p53 and TCTP
antagonize each other. Similar evidence comes from a
diﬀerent observation. The dsRNA-dependent protein kinase
(PKR) increases p53 transcriptional function [89]. Mice
depleted of PKR had altered TCTP protein levels. Further
analysis showed that PKR directly interacts with TCTP
mRNA. This interaction is required for PKR activation [9].
Hence, the presence of PKR might sequester TCTP mRNA
and remove free TCTP mRNA from the RNA pool that
would otherwise be available for translation. Hence, a higher
level of PKR might be associated with lower TCTP protein
levels. As PKR activates p53 and counteracts TCTP, it adds
another layer of antagonistic control between TCTP and p53.
The level of both p53 and TCTP might determine which
pathway to choose, cell cycle arrest or apoptosis.
As outlined above, TCTP misregulation has an impact
on the TOR pathway, apoptosis, reprogramming and cell
cycle. All of these pathways can be implicated in cancer
when they do not function correctly. In the TOR pathway,
overexpression or mutations enhancing TCTP activity might
result in increased TOR activation, leading to enhanced
cell growth and ultimately tumor formation. Similarly,
alterations in TCTP level might alter the ability of TCTP to
inhibit apoptosis. Any TCTP misregulation might prevent
damaged cells from being eliminated by apoptosis and in
this way promote the survival of cells that might result in
cancerous cells. Nuclear transfer experiments have shown
that TCTP induces the transcription of pluripotency genes
such as Oct4 and Nanog. An increased level of TCTP in
normal cells may promote the formation of pluripotent-
like gene expression. This might partly reprogram quiescent
diﬀerentiated cells into pluripotent like proliferating cells.
If in addition mutations accumulate in these cells, elevated
levels of TCTP might enhance the propagation of these
mutated cells. The higher the level of pluripotency transcripts
is, the greater is the cell’s malignant potential [90]. This
suggests that this is also true for a higher TCTP level.
Ultimately, this can result in cancer. Misregulation of TCTP
might also impact cell cycle progression by interfering
with PLK1. PLK1 is overexpressed in a range of human
tumors, and PLK1 overexpression is associated with a bad
cancer prognosis [91]. Since PLK1 phosphorylates TCTP
that is required for cell cycle progression from mitosis, it
is possible that an overexpression of PLK1 causes faster
TCTP phosphorylation and cell cycle progression. This faster
cell cycle progression might result in cell cycle progression
even when mitosis is not complete. The resulting daughter
cells could in this way inherit not fully replicated genomes.
This might result in a vast amount of mutations that might
result in cancer. Alternatively, TCTP could be mutated, being
irresponsive to PLK1, and have the same eﬀect.
Finally, TCTP is also known to be involved in protein
synthesis by acting as a guanine nucleotide dissociation
inhibitor for the elongation factor EF1A [18]. Any changes in
TCTP level could influence many genes at once and change
the status of a cell substantially. Similarly, changes in TCTP
will also aﬀect the immune response and ultimately might
promote cancer development [19].
7. Conclusion
In summary, TCTP is highly conserved and abundant. It
is involved in many key biological pathways, such as the
TOR pathway, apoptosis, nuclear reprogramming, and cell
cycle. It is highly regulated on a transcriptional, translational
and protein level. As TCTP is involved in a wide array of
biological functions, it is not surprising that any changes to
TCTP might result in an array of abnormal phenotypes. Fur-
thermore, abnormal cell proliferation, growth, and survival
are probably the most important characteristics of cancer,
all of which are regulated by TCTP. Due to this involvement,
and its presence in many other pathways, TCTP might be a
crucial target for cancer therapies. Some success has already
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been reported in this regard [11]. Bearing in mind that
TCTP is also a histamine-releasing factor, inhibitors of this
pathway were tested for their ability to decrease the number
of tumor cells by inhibiting TCTP. In fact, many of such
inhibitors were found to kill tumors [11]. However, further
studies are required to better understand the function of
TCTP in the pathways described before and maybe to reveal
further functions. Overall, this will greatly contribute to
the understanding of basic molecular pathways and provide
further target sites for cancer therapies.
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